T-type Ca channel blockade as a determinant of kidney protection

Keio Journal of Medicine

Volumn 59, Issue 3, 2010, Pages 84-95

  Hayashi, Koichi ^a   Homma, Koichiro ^a   Wakino, Shu ^a   Tokuyama, Hirobumi ^a   Sugano, Naoki ^a   Saruta, Takao ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Efonidipine; Renal microcirculation; T type calcium channels; Voltage dependent Ca channels

Indexed keywords

AMLODIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CILNIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; FELODIPINE; MEPIRODIPINE; MIBEFRADIL; NIFEDIPINE; NILVADIPINE;

CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD VESSEL; MICROCIRCULATION; NONHUMAN; RENAL PROTECTION; REVIEW;

EID: 78249284594     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.59.84     Document Type: Review

References (103)

1. Heller J, Horacek V: The effect of two different calcium antagonists on the glomerular haemodynamics in dogs. Eur J Physiol 1990; 415: 751-755.
2. Dietz JR, Davis JO, Freeman RH, Villarreal D, Echtenkamp SF: Effects of intrarenal infusion of calcium entry blockers in anesthetized dogs. Hypertension 1983; 5: 482-488.
3. Roy M, Guthrie GP, Holladay FP, Kotchen TA: Effects of vera-pamil on renin and aldosterone in the dog and rat. Am J Physiol 1983; 245: E410-E416.
4. Carmines PK, Navar LG: Disparate effects of Ca channel blockers on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989; 256: F1015-F1020.
5. Loutzenhiser R, Epstein M, Horton C, Sonke P: Reversal by the calcium antagonist nisoldipine of norepinephrine-induced reduction of GFR: evidence for preferential antagonism of preglomeru-lar vasoconstriction. J Pharmacol Exp Ther 1984; 232: 382-387.
6. Loutzenhiser R, Epstein M: Renal hemodynamic effects of calcium antagonists. In: Epstein M, Loutzenhiser R (eds) Calcium Antagonists and the Kidney. Philadelphia, Hanley & Belfus, 1990, pp 33-74.
7. Fleming JT, Parekh N, Steinhausen M: Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 1987; 253: F1157-F1163.
8. Nagahama T, Hayashi k, Fujiwara K, Ozawa Y, Saruta T: Charac- terization of the renal action of pranidipine in the rat. Arzneimittel Forschung 2000; 50: 248-253.
9. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987; 252: F1003-F1010.
10. Griffin KA, Picken M, Bidani AK: Method of renal mass reduction is a critical determinant of subsequent hypertension and glo-merular injury. J Am Soc Nephrol 1994; 4: 2023-2031.
11. Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockers on pressures transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793-800.
12. Griffin KA, Picken MM, Bakris GL, Bidani AK: Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849-1860.
13. Ertel EA, Campbell KP, Harpold MM, et al: Nomenclature of voltage-gated calcium channels. Neuron 2000; 25: 533-535.
14. Perez-Reyes E: Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003; 83: 117-161.
15. Ono K, Iijima T: Pathophysiological significance of T-type Ca2+ channels: properties and functional roles of T-type Ca2+ channels in cardiac pacemaking. J Pharmacol Sci 2005; 99: 197-204.
16. Hansen PB, Jensen BL, Andreasen D, Friis UG, Skott O: Vascular smooth muscle cells express the alpha(1A) subunit of a P-/Q-type voltage-dependent Ca(2+) channel, and it is functionally important in renal afferent arterioles. Circ Res 2000; 87: 896-902.
17. Hansen PB, Jensen BL, Andreasen D, Skøtt O: Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
18. Shudo C, Masuda Y, Sugita H, Furukawa S, Hayashi K, Hirata H, Tanaka S, Tomita K: Renal protective effect of efonidipine hydro-chloride (NZ-105), a new calcium antagonist, in spontaneously hypertensive rats. Gen Pharmacol 1994; 25: 1567-1575.
19. Fujiwara K, Kanno Y, Hayashi K, Takenaka T, Saruta T: Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998; 20: 295- 312.
20. Karam H, Clozel J-P, Bruneval P, Gonzalez M-F, Ménard J: Contrasting effects of selective T- an L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. Hypertension 1999; 34: 673-678.
21. Hayashi K, Kumagai H, Saruta T: Effects of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116-122.
22. Baylis C, Qiu C, Engels K: Comparison of L-type and mixed Land T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats. Am J Kidney Dis 2001; 38: 1292-1297.
23. Omae K, Ogawa T, Nitta K: Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels 2009; 24: 301-307.
24. Jurkat-Rott K, Lehmann-Horn F: The impact of splice isoforms on voltage-gated calcium channel α1 subunits. J Physiol 2003; 554; 609-619.
25. Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov NM: Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel α1C subunit. Proc Natl Acad Sci USA 2006; 103: 17024-17029.
26. Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic pep-tide causes pre-glomerular vasodilatation and post-glomerular va-soconstriction in rat kidney. Nature 1986; 324: 473-476.
27. Loutzenhiser R, Hayashi K, Epstein M: A trial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. J Pharmacol Exp Ther 1988; 246: 522-528.
28. Hayashi K, Epstein M, Loutzenhiser R: Pressure-induced vaso-constriction of renal microvessels in normotensive and hypertensive rats: studies in the isolated perfused hydronephrotic kidney. Circ Res 1989; 65: 1475-1484.
29. Loutzenhiser R, Epstein M, Hayashi K, Horton C: Direct visualization of effects of endothelin on the renal microvasculature. Am J Physiol 1990; 258: F61-F68.
30. Loutzenhiser R, Hayashi K, Epstein M: Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol 1989; 257: F561-F564.
31. Bührle CP, Nobiling R, Taugner R: Intracellular recordings from renin-positive cells of the afferent glomerular arteriole. Am J Physiol 1985; 249: F272-F281.
32. Carmines PK, Fower BC, Bell PD: Segmental distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol 1993; 265: F677-F685.
33. Steinhausen M, Baehr M: Vasomotion and vasoconstriction induced by a Ca agonist in the split hydronephrotic kidney. Prog Appl Microcirc 1989; 14: 25-29.
34. Reams GP, Bauer JH: Acute and chronic effects of calcium antagonists on the essential hypertensive kidney. In: Epstein M, Lout-zenhiser R (eds) Calcium Antagonists and the Kidney. Philadelphia, Hanley & Belfus, 1990, pp 247-256.
35. Ichikawa I: Will angiotensin II receptor antagonists be renopro-tective in humans? Kidney Int 1996; 50: 684-692.
36. Loutzenhiser R, Horton C, Epstein M: Effects of diltiazem and manganese on renal hemodynamics: studies in the isolated perfused rat kidney. Nephron. 1985; 39: 382-388.
37. Loutzenhiser R, Epstein M, Fischetti F, Horton C: Effects of am-lodipine on renal hemodynamics. Am J Cardiol 1989; 64: 122I- 127I.
38. Loutzenhiser R, Epstein M: Modification of the renal hemody-namic response to vasoconstrictors by calcium antagonists. Am J Nephrol 1987; 7 (Suppl 1): 7-16.
39. Edwards RM: Segmental effects of norepinephrine and angioten-sin II on isolated renal microvessels. Am J Physiol. 1983; 244: F526-F534.
40. Yuan B, Robinette JB, Conger JD: Effects of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 1990; 258: F741-F750.
41. Ito S, Carretero OA: An in vitro approach to the study of macula densa-mediated glomerular hemodynamics. Kidney Int 1990; 38: 1206-1210.
42. Ito S, Ren Y: Evidence for the role of nitric oxide in macula densa control of glomerular hemodynamics. J Clin Invest 1993; 92: 1093-1098.
43. Casellas D, Navar LG: In vitro perfusion of juxtamedullary neph-rons in rats. Am J Physiol 1984; 246: F349-F358.
44. Steinhausen M, Snoei H, Parekh N, Baker R, Johnson PC: Hydro-nephrosis: A new method to visualize vas afferens, efferens, and glomerular network. Kidney Int 1983; 23: 794-806.
45. Yamamoto T, Hayashi K, Matsuda H, et al: In vivo visualization of tubuloglomerular feedback- and angiotensin II-induced renal vasoconstriction in dogs by an intravital pencil lens-probe video-microscope. Kidney Int 2001; 60: 364-369.
46. Carmines PK, Navar LG: Disparate effects of Ca channel blockers on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989; 256: F1015-F1020.
47. Arima S, Ito S, Omata K, Tsunoda K, Yaoita H, Abe K: Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int Suppl 1996; 55: S132-S134.
48. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T: Disparate effects of calcium antagonists on renal microcirculation. Hyper-tens Res 1996; 19: 31-36.
49. Saruta T, Kanno Y, Hayashi K, Konishi K: Antihypertensive agents and renal protection: Calcium channel blockers. Kidney Int 49 (Suppl) 1996; 55: S52-S56.
50. Honda M, Hayashi K, Matsuda H, et al: Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hyper-tens 2001; 9: 2031-2037.
51. Takabatake T, Ohta H, Sasaki T, Satoh S, Ohta K, Ise T, Kobayas-hi K: Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients. Eur J Clin Pharmacol 1993; 45: 321-325.
52. rd ed.). Hanley & Belfus, pp559- 578, 2002.
53. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Wakino S, Saruta T: Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. J Cardio-vasc Pharmacol 1999; 33: 243-247.
54. 2+ currents by efonidipine: possible mechanism for chronotropic effect. Eur J Pharmacol 1998; 349: 351-357.
55. Nakamura Y, Ono H, Frohlich ED: Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension 1999; 34: 273-278.
56. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T: Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension 2001; 38: 343-347.
57. Zhou X, Ono H, Ono Y, Frohlich ED: N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 2002; 20: 993-1000.
58. Kimura K, Suzuki N, Ohba S, Mise N, Miyashita K, Tojo A, Goto A, Omata M: Effects of amlodipine, a calcium channel blocker, on rat renal arterioles. Curr Ther Res 1997; 58: 375-380.
59. Hosono M, Fujii S, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, Takata Y, Kato H: Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol 1995; 69: 127-134.
60. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA: The evaluation of the N-type channel blocking properties of cilnidip-ine and other voltage-dependent calcium antagonists. Fundam Clin Pharmacol 2004; 18: 309-319.
61. Takahara A, Dohmoto H, Hisa H, Satoh S, Yoshimoto R: Cilnidip-ine attenuates renal nerve stimulation-induced renal vasoconstric-tion and antinatriuresis in anesthetized dogs. Jpn J Pharmacol. 1997; 75: 27-32.
62. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
63. Yoshioka T, Shiraga H, Yoshida Y, Fogo A, Glick AD, Deen WM, Hoyer JR, Ichikawa I: "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 1988; 82: 1614-1623.
64. Harris DC, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal disease. Kidney Int 1987; 31: 41-46.
65. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996; 27: 245- 250.
66. Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992; 20: 233-241.
67. Pelayo JC, Westoo JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 1991; 88: 101-105.
68. Shudo C, Masuda Y, Sugita H: Beneficial effect of efonidipine hydrochloride (NZ-105) on proteinuria in aged spontaneously hypertensive rats (SHR). Pharm Sci 1995; 1: 333-335.
69. Shudo C, Masuda Y, Sugita H, et al: Effects of efonidipine, nicar-dipine and captopril on proteinuria in aged spontaneously hypertensive rats. Arzneimittel Forschung 1996; 46: 852-854.
70. Konda T, Enomoto A, Takahara A, Yamamoto H: Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006; 29: 933 -937.
71. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T: The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101: 1-13.
72. Fujiwara K, Hayashi K, Kanno Y, Takenaka T, Saruta T: Renal protective effects of efonidipine hydrochloride in subtotally ne-phrectomized spontaneously hypertensive rats. Clin Exp Hyper-tens 1998; 23: 295-312.
73. Sugiura T, Imai E, Moriyama T, Horio M, Hori M: Calcium channel blockers inhibit proliferation and matrix production in rat me-sangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron 2000; 85: 71-80.
74. Roth M, Keul R, Emmons LR, Horl WH, Block LH: Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA 1992; 89: 4071-4075.
75. Hayashi M, Yamaji Y, Nakazato Y, Saruta T: The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangial cells. Hypertens Res 2000; 23: 521-525.
76. Fukuo K, Yang J, Yasuda O, et al: Nifedipine indirectly upregu-lates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation 2002; 106: 356-361.
77. Rossier MF, Ertel EA, Vallotton MB, Capponi AM: Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J Pharmacol Exp Ther. 1998; 287: 824-831.
78. Somekawa S, Imagawa K, Naya N, et al: Regulation of aldoste-rone and cortisol production by the transcriptional repressor neuron restrictive silencer factor. Endocrinology, 2009; 150: 3110-3117.
79. Tanaka T, Tsutamoto T, Sakai H, Fuji M, Yamamoto T, Horie M: Comparison of the effects of efonidipine and amlodipine on aldo-sterone in patients with hypertension. Hypertens Res 2007; 30: 691-697.
80. Ishimitsu T, Kameda T, Akashiba A, et al: Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glo-merulonephritis. Hypertens Res 2007; 30: 621-626.
81. Rudolph AE, Rocha R, McMahon EG: Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol. 2004; 217: 229- 238.
82. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T: Effect of fasudil on Rho-kinase and nephropathy in subtotally ne-phrectomized spontaneously hypertensive rats. Kidney Int. 2003; 64: 2009-2019.
83. Nishikimi T, Akimoto K, Wang X, et al: Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens. 2004; 22: 1787-1796.
84. Nishikimi T, Matsuoka H: Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of Rho-ki-nase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci 2006; 100: 22-28.
85. Ruperez M, Sanchez-Lopez E, Blanco-Colio LM, Esteban V, Rodriguez-Vita J, Plaza JJ, Egido J, Ruiz-Ortega M: The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int Suppl. 2005; 99: S39-S45.
86. Uehata M, Ishizaki T, Satoh H, et al: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
87. Sugano N, Wakino S, Kanda T, et al: T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008; 73; 826-834.
88. Zhao D, Pothoulakis C: Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 2003; 7: 583-592.
89. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretics. JAMA 2003; 288: 2981-2997.
90. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G: Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164; 2459-2464.
91. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2002; 285: 2719-2728.
92. Ruggenenti P, Perna A, Loriga G, et al; REIN-2 Study Group: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-946.
93. Pohl MA, Blumenthal S, Cordonnier DJ, et al: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic ne-phropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-337.
94. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303-1309.
95. Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A: Impact of renin-an-giotensin system inhibition on microalbuminuria in type 2 diabe- tes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). Hypertens Res 2008; 31: 1171-1176.
96. Hasebe N, Kikuchi K; NICE Combi Study Group: Controlled-re-lease nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445- 453.
97. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K: Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321-326.
98. Ogawa S, Mori T, Ito S: Combination therapy with renin-angio-tensin system inhibitors and the calcium channel blocker azelni-dipine decreases plasma inflammatory markers and urinary oxida-tive stress markers in patients with diabetic nephropathy. Hyper-tens Res 2008; 31: 1147-1155.
99. Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K: Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005; 27: 583-591.
100. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators: Kidney Int 2007; 772: 1543-1549.
101. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K: Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32: 270-275.
102. Hart P, Bakris GL: Calcium antagonists: Do they equally protect against kidney injury? Kidney Int 2008; 73: 795-796.
103. Ge W, Ren J: Combined L-/T-type calcium channel blockers: ready for prime time. Hypertension 2009; 53: 592-594.